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Abstract
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare, highly malignant, extranodal
lymphoma that preferentially infiltrates into subcutaneous adipose tissue. No case of SPTCL with the earliest
symptoms occurring in the eye region has been reported. We report a case of SPTCL complicated by eyelid
swelling.
Case presentation: A 19-year-old Japanese man presented with worsening left eyelid swelling. The patient’s
best-corrected visual acuity (BCVA) was 0.8, left intraocular pressure was 36 mm Hg, and he had prominent
mucosal hyperemia and edema. His left eye had light reflex attenuation and a positive relative afferent pupillary
defect, but no abnormality in the visual field or central flicker value. Magnetic resonance imaging showed left
orbital adipose tissue inflammation. The blood examination was normal. He was hospitalized for an intensive
examination and treatment for possible cellulitis, orbital panniculitis, and inflammatory pseudotumor. Systemic
antibiotics were initiated. The following day, he underwent a sub-Tenon’s injection of triamcinolone. Left eyelid
swelling gradually improved. He was discharged on the ninth day and followed up with oral prednisolone.
Two months later, he visited our department because of a high fever and slight right eyelid swelling. Ocular
hypertension was detected. A blood examination revealed pancytopenia. Computed tomography showed fluid
retention, hydrothorax, and abdominal dropsy. Magnetic resonance imaging revealed right orbital panniculitis.
Because of suspected hemodyscrasia, he was referred to the hematology department of another hospital where
he was diagnosed with SPTCL.
Conclusions: The possibility of SPTCL, with attention to recurrence and systemic symptoms, should be considered in
young patients with sudden eyelid swelling.
Keywords: Subcutaneous panniculitis-like T-cell lymphoma, Eyelid swelling, Mucosal hyperemia, Ocular hypertension,
Pancytopenia, Case report
Background
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
is a cytotoxic T-cell lymphoma that preferentially infil-
trates into subcutaneous adipose tissue [1]. It is a rare
disorder and represents less than 1 % of all non-Hodgkin
lymphomas [2]. SPTCL is accompanied by fever, arthral-
gia, and hepatopathy as systemic symptoms, which cause
hemophagocytic syndrome (HPS) in many patients [3].
In 1991, Gonzalez et al. [4] reported eight patients with
similar clinicopathologies who exhibited a pathological
mechanism of subcutaneous tissue-originated T-cell ma-
lignant lymphoma, which resulted in a poor prognosis
after being complicated by HPS. In 1994, SPTCL was pro-
posed as a provisional subtype of peripheral T-cell lymph-
oma under the Revised European American Lymphoma
(REAL) classification [5]. In 2001, a new World Health
Organization (WHO) classification established SPTCL as
an independent disease [6]. Subcutaneous nodules focused
on the extremities and trunk are frequently the initial
symptoms of SPTCL, and they frequently accompany sys-
temic symptoms [3]. Among the malignant lymphomas,
* Correspondence: ryuyah@gmail.com
1Department of Ophthalmology, Toho University Sakura Medical Center,
564-1 Shimoshizu, Sakura 285-8741, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hashimoto et al. BMC Ophthalmology  (2016) 16:117 
DOI 10.1186/s12886-016-0303-4
the initial symptoms of SPTCL tend to appear in relatively
young patients, with a mean age of onset of 33 years [7].
No standard treatment for SPTCL has been established.
However, various treatments such as chemotherapy, radio-
therapy, bone marrow transplantation, and immunosup-
pressive therapy have been reported [1, 2].
To our knowledge, no case of SPTCL with the earliest
symptoms presenting in the eye region has been re-
ported. In this paper, we report a case of SPTCL compli-
cated by swelling in one eyelid, which was the original
symptom. The eyelid swelling temporarily improved
with treatment. Approximately 3 months after the initial
treatment, systemic symptoms and SPTCL reappeared,
complicated by swelling of the opposite eyelid.
Case presentation
A 19-year-old Japanese man developed left eyelid swell-
ing around October 2, 2013. On October 9, 2013, he vis-
ited the ophthalmologic department of a local hospital
because of subsequent gradually worsening ophthalmal-
gia and visual deterioration. The symptoms did not im-
prove after the ocular administration of antibiotics. He
was referred to Toho University Sakura Medical Center
in Sakura, Japan (referred to hereafter as “our hospital”)
on October 16, 2013, with a main complaint of left
eyelid swelling. He had no medical, family medical, or
allergy history. At the first visit, his right best-corrected
visual acuity (BCVA) was 1.2; his left BCVA was 0.8 with
visual deterioration. His right and left intraocular pres-
sures (IOPs) were 17 mmHg and 36 mmHg, respectively.
Prominent left eyelid swelling and exophthalmos were
evident (Fig. 1a). A slit-lamp examination revealed
prominent mucosal hyperemia, edema, and slight mu-
cous discharge (Fig. 1b). Moderate mydriasis of the left
pupil, direct light reflex attenuation, and positive relative
afferent pupillary defect (RAPD) were present. No ab-
normality existed in the corneas, lenses, retinas, or optic
nerve heads; however, ocular motility was omnidirec-
tionally circumscribed. Dynamic campimetry showed
neither central scotoma nor visual field deficiency. No
laterality of central flicker values was revealed on central
flicker examination. No systemic symptoms such as
fever or infection were found on physical examination at
the first visit. The blood examination exhibited a normal
inflammatory response value.
Orbital magnetic resonance imaging (MRI) showed
soft tissue swelling in the left orbital muscle cone, and
orbitographic MRI showed systematic trachychromatic
images in the periorbital soft tissues (Fig. 2).
Clinical findings indicated suspected orbital cellulitis,
although the blood examination exhibited no increase in
the inflammatory response value. Intraorbital inflamma-
tory pseudotumor was a differential diagnosis because of
suspected orbital panniculitis on diagnostic MRI. He was
Fig. 1 The patient’s face and left anterior ocular segment at the first visit. a The patient exhibits prominent left eyelid swelling and exophthalmos.
b A photograph demonstrates prominent mucosal hyperemia, edema, and moderate mydriasis of the pupil
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hospitalized. An intravenous infusion of betamethasone
(4 mg/day) was started on October 16, 2013.
The following medications were started at the first
visit because of the possibility of orbital cellulitis: ocular
administration of levofloxacin four times daily and
cefmenoxime four times daily, ofloxacin ophthalmic
ointment once daily, and intravenous infusions of imipe-
nem/cilastatin (0.5 g × 3 times daily). Culture identifica-
tion of the eye discharge was also performed on the
same day. Oral administration of acetazolamide tablets
(300 mg × 3 × 3 times daily) and potassium L-aspartate
tablets (300 mg × 3 × 3 times daily) was also started
because of left ocular hypertension. We supposed that
there might be another possibility of an immunologic or
inflammatory pseudo tumor besides orbital cellulitis
because of the few inflammatory clinical findings; thus,
we tried to use a sub-Tenon’s injection of triamcinolone
as a diagnostic therapy. A sub-Tenon’s injection of
triamcinolone (0.5 mg) in the left eye on the first day of
hospitalization resulted in improvements in mucosal
hyperemia and edema and the disappearance of eyelid
swelling (Fig. 3). The left BCVA improved to 1.2, there
was a reduction in left IOP to 15 mmHg, and the left
eyelid swelling nearly disappeared and did not recur.
Mucosal hyperemia and edema were observed on the
sixth day of hospitalization. Improvement of the left
orbital panniculitis compared to the image acquired at
the first visit was revealed by orbitographic MRI on the
seventh day of hospitalization. He was discharged on the
ninth day of hospitalization. Left and right IOPs
gradually declined to approximately 15 mm Hg at
discharged. Systemic and local administrations of antibi-
otics were discontinued on the seventh day of
hospitalization because a culture of the eye discharge,
which was performed at the first visit, had returned
negative results. Oral prednisolone (30 mg/day) was
started after hospital discharge. There was no recurrence
of ocular symptoms and a favorable progression in vision
to 1.2, despite a gradual reduction of prednisolone. Fa-
vorable progress in the left ocular tension to approxi-
mately 15 mmHg also occurred with the discontinuation
of oral acetazolamide tablets and the initiation of the
Fig. 2 Orbitographic magnetic resonance imaging and a T2-weighted image from the first visit. a A systematic trachychromatic image of the left
periorbital soft tissues and (b) soft tissue in the left orbital muscle cone is swollen, and the left eyeball is protruding
Fig. 3 The anterior ocular segment before and after treatment. Images of the patient’s eyes (a) before treatment (October 16, 2013) and (b) after
treatment (January 4, 2014) are shown. The mucosal hyperemia and edema improved, and the eye swelling disappeared by the third month after
starting treatment
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ocular administration of dorzolamide hydrochloride/
timolol maleate (twice) and latanoprost (once).
Symptoms had not recurred when he was examined at
an ambulatory follow-up visit on January 8, 2014. On
January 20, 2014, he visited the internal medicine de-
partment of a local hospital and was orally administered
antibiotics because of a subsequent fever of 39 °C and
appendicular arthralgia. The symptoms did not improve,
despite the oral antibiotic administration. A subsequent
blood examination exhibited pancytopenia, hepatopathy,
and an increased lactate dehydrogenase (LDH) level. He
immediately revisited our department for an intensive
examination and treatment on January 29, 2014 (the
15th week after the first visit) with a complaint of slight
swelling of the right eyelid, whereas swelling of the left
eyelid was observed at the first visit.
Ophthalmological findings at the second visit revealed
slight right eyelid swelling (Fig. 4). The BCVA of both
eyes was 1.2, but the intraocular pressure was 25 mmHg
in the right eye and 27 mmHg in the left eye. Slight
direct light reflex attenuation of both eyes was present,
and positive RAPD of the right eye was also found. No
abnormality was found in dynamic campimetry or a
central flicker examination. However, orbitographic MRI
showed right exophthalmos and orbital soft tissue
inflammation. Left orbital panniculitis, which had
improved (compared to the image acquired at the first
visit), had recurred, compared to the image acquired
during hospitalization on October 23, 2013 (Fig. 5).
Systemic findings included a high body temperature of
39.8 °C and tachycardia of 103 beats per minute. A
blood examination revealed leucocyte and thrombocyte
cytopenia, hepatopathy, and increased coagulability:
leucocytes, 3220/mm3; thrombocytes, 11.1 × 104 mm3;
aspartate transaminase/alanine transaminase (AST/ALT)
level, 115/91 IU/L; LDH level, 1014 IU/L; creatinine kin-
ase level, 362 IU/L; prothrombin time, 13.6 s; activated
partial thromboplastin time (APTT), 37 s; and D-D dimer,
2.17 s. He visited the internal medicine department of our
hospital for an intensive examination. Abdominal echo-
graphy and abdominal/pelvic computed tomography
(CT) showed moderate retention of abdominal fluid,
dropsy, and an enlarged spleen.
He was transferred to the hematology department at
another hospital and was hospitalized for an intensive
examination on the following day because of the possi-
bility of hemodyscrasia, based on the increased LDH
level in the blood examination results. Bone marrow
aspiration examined after the hospital transfer revealed
decreased numbers of nucleated cells and megakaryo-
cytes and a small amount of corpuscular phagocytosis. A
blood examination revealed leucocyte and thrombocyte
cytopenia; increased levels of AST/ALT, LDH, and
ferritin; and hepatopathy. Antibodies against herpes
simplex virus, cytomegalovirus, and Epstein–Barr virus
were negative.
Steroid administration (30 mg/day) was started with a
diagnosis of HPS. After 1 week, he left the hospital
because his symptoms improved. However, bubonalgia
appeared immediately after hospital discharge and did
not improve. He revisited the hospital on February 29,
2014. Abdominal CT exhibited suspected panniculitis in
vesicular subcutaneous tissue. Cyclosporine was admin-
istered because of suspected Weber–Christian disease.
The hepatopathy and increased levels of LDH and fer-
ritin did not improve. Worsening HPS was diagnosed
because of the appearance of a high fever (39.5 °C) on
the morning of March 20, 2014. A biopsy of the vesicu-
lar ventral subcutaneous adipose tissue by hypogastric
transection was also performed in the anaplastic depart-
ment of a local hospital on the same day. The histo-
pathological diagnosis of the biopsy tissue revealed an
aggregating tendency of nuclear irregularity-prominent
atypical lymphocytes in the adipose tissue. SPTCL was
diagnosed because of the surrounding arrangement (i.e.,
rimming pattern) of lipid droplets (Fig. 6). On May 1,
2014, two aggregations of fluorodeoxyglucose in the right
ilium were detected by positron emission tomography
Fig. 4 The patient’s face at recurrence. The patient shows slight right eyelid swelling (i.e., the opposite eyelid)
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(PET) examination. Advanced malignant lymphoma was
also suspected, based on the pelvic MRI findings. He was
transferred to Suwa Red Cross Hospital (Suwa, Japan) on
May 1, 2014 because of his requirements for intensive
examination and treatment.
After the hospital transfer, histopathological and immu-
nohistological re-examinations of the vesicular adipose
tissue exhibited poor infiltration of atypical lymphocytes
into the dermis. Immunohistological findings exhibited
positivity for CD3, CD8, granzyme B, T-cell intracellular
antigen-1 (TIA-1), and beta F1; and negativity for C-
gamma M1, CD30, CD56, and Epstein–Barr virus-
encoded small RNAs (EBERs), which led to a definitive
diagnosis of αβ-type SPTCL. He was hospitalized for
treatment on May 21, 2014. The standard treatment for
malignant lymphomas—cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) therapy—was admin-
istered for 5 days, and presented no efficacy. Four courses
of etoposide, methylprednisolone sodium succinate, high-
dose cytarabine, and platinum chemotherapy were admin-
istered beginning on June 11, 2014. On September 26,
2014, he underwent autologous peripheral stem cell trans-
plantation because his symptoms were controlled. Hos-
pital treatment for 6 months resulted in remission of his
symptoms. Remission has been maintained.
Conclusions
The patient originally presented with swelling of one
eyelid complicated by visual deterioration. Systemic
symptoms such as high fever, abdominal dropsy, and
hepatosplenomegaly subsequently appeared after the
temporary improvement of symptoms by local/systemic
steroid administration. This improvement was followed
by swelling of the right (i.e., the opposite) eyelid. The
findings at the first visit were similar to findings of
orbital cellulitis. No fever and no increase in the inflam-
matory response value were indicated by the blood
examination. Previous cases of SPTCL have been re-
ported with many patients originally presenting with
subcutaneous nodules on the trunk and/or extremities,
and systemic symptoms such as fever and arthralgia [3].
No case of opposite eyelid swelling with systemic
Fig. 5 Orbitographic magnetic resonance imaging at recurrence. Right exophthalmos (a) and orbital softtissue inflammation (b) are evident
Fig. 6 The histopathological findings of the vesicular subcutaneous tissue. The immunohistochemistry shows that the infiltrating lymphocytes are
positive for CD8. There is an aggregating tendency of atypical lymphocytes and a surrounding arrangement (i.e., rimming image) of lipid droplets
(CD8, magnification, 400×)
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symptoms occurring after temporary symptom improve-
ment without systemic involvement in the early stages of
SPTCL has been reported previously.
This case of SPTCL was very difficult to differentiate.
The appearance of facial symptoms is rare; based on 83
recently reported cases, the original appearance of symp-
toms was on the face in only 16 cases, compared to the
lower extremities in 64 cases, the upper extremities in
52 cases, and the trunk in 47 cases [7].
SPTCL is difficult for doctors in other departments to
differentiate, and frequently leads to a first diagnosis of
cellulitis or subcutaneous panniculitis. Symptoms of
eyelid swelling occur in orbital phlegmon, orbital inflam-
matory pseudotumor, immunoglobulin G4 (IgG4)-related
diseases, malignant orbital lymphomas, and collagenosis
such as scleroderma and systemic lupus erythematosus.
Orbital cellulitis was excluded from the differential
diagnosis during the treatment process, based on clinical
findings such as the absence of fever and lymphoma at
the first visit, the absence of an increase in inflammatory
response value in the blood examination, and no detec-
tion of pathogenic bacteria in the culture identification
of the eye discharge. Furthermore, collagenosis and
IgG4-related diseases were excluded because the blood
examination detected no autoantibody accompanying
collagenosis and because of the normal IgG value.
Malignant orbital lymphomas, an important differen-
tial disease, frequently appear with eyelid swelling as the
original symptom. Most orbital malignant lymphomas
accompany B-cell lymphomas, which exhibit relatively
good prognoses compared with prognoses of malignant
lymphomas originating in other regions. Orbital malig-
nant lymphomas often occur in young adults; however,
the onset is usually in old age [8–10]. MRI examination
demonstrates the boundaries of tumors more clearly in
malignant lymphomas than in orbital inflammatory
pseudotumors [11, 12], although a pathological examin-
ation is required for a definitive diagnosis of malignant
lymphoma.
Progress observation instead of a highly invasive
biopsy of the orbital soft tissue was performed in this
patient after consultation with neurosurgeons at our
hospital because of the rapid improvement of symptoms
after the initial and steroid treatments and the lack of re-
currence. Orbital malignant lymphoma was excluded be-
cause of the young age of onset (19 years), the early
remission of symptoms after steroid administration, and
the uniform staining of soft tissue indicated by MRI.
Therefore, the initial treatment for the most suspected
disease—orbital panniculitis—was started. It is necessary
to attempt to detect diseases early by biopsy, gallium
scintigraphy, and PET examinations (depending on pro-
gress observation) because of the possibility of orbital
malignant lymphoma and metastases from other organs.
SPTCL is divided into the αβ-type and the γδ-type,
based on histopathological and immunohistological find-
ings. The prognoses differ between these two types.
Because complications occur more frequently in γδ-type
SPTCLs with HPS than in αβ-type SPTCLs during the
clinical course, the prognoses of αβ-type SPTCLs are
relatively better than the prognoses of γδ-type SPTCLs,
which are complicated frequently by HPS [7]. Massone
et al. [13] reported that the 5-year survival rate of αβ-
type SPTCL was approximately 80 %. On the other
hand, investigators of a European multicenter study [7]
reported that the 5-year survival rates among 63 cases of
αβ-type SPTCL were 46 % for HPS-complicated cases
(11 cases) and 91 % for cases not complicated with HPS
(52 cases), and that the 10-year survival rates were
equivalent to the 5-year survival rates.
No standard treatment for SPTCLs has been estab-
lished. However, various treatments such as chemother-
apy, radiotherapy, bone marrow transplantation, and
immunosuppressive therapy have been reported, and pa-
tients frequently respond to oral steroid administration
in the early stage of the disease and easily respond to
combination chemotherapy [1, 2, 14].
With regard to the possibility of symptom relapse after
the reduction of steroid treatment, the reappearance of
systemic symptoms after the discontinuation of oral ster-
oid treatment after temporary symptom remission
resulting from betamethasone infusion and oral steroid
administration is consistent with the progression of
SPTCL in this patient. The reasons for the improvement
in eyelid margin swelling with steroid administration in
the early stage of the disease may have been related to
responses to anti-inflammatory and antitumor actions.
No standard treatment for SPTCLs has been established,
although the effectiveness of peripheral stem cell trans-
plantation within 1 year of onset has been reported.
When symptoms appear and/or worsen during treat-
ment, an early and accurate histopathological diagnosis
by biopsy in the early stage should be performed, and
peripheral stem cell transplantation should be consid-
ered as an alternative.
SPTCL is a relatively novel concept. Possible cases of
SPTCLs previously diagnosed as Weber–Christian dis-
ease and HPS cannot be denied. Because there are fewer
cytotoxic T-cells with positivity for CD8 in the initial
SPTCL lesion, a re-examination of biopsy tissue often
exhibits a characteristic picture and histology of SPTCL
after the diagnosis of Weber–Christian disease, lupus
profundus, or HPS by a histopathological diagnosis in
the early stage of the disease. Therefore, when SPTCL is
suspected, and even when SPTCL is excluded by the
initial biopsy, the necessity of biopsy re-examination
without hesitation should be kept in mind. SPTCL,
which is even likely to appear in young adults, is a very
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rare disease. Delays in diagnosis and/or treatment may
influence the vital prognosis.
This rare case of SPTCL originally presented with eye-
lid symptoms, no fever, and no systemic symptoms, such
as hepatosplenomegaly. This case subsequently exhibited
systemic symptoms and swelling of the opposite eyelid
after a certain period of time. When rapidly worsening
eyelid swelling occurs in relatively young adults, the
possibility of hemodyscrasia such as SPTCL should be
considered. Furthermore, the appearance of systemic
symptoms and the recurrence of eyelid swelling should
be considered during progress observation.
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